Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is a United States health technology company that applies artificial intelligence to precision medicine. Founded in 2015 by Eric Lefkofsky in Chicago, Illinois, Tempus was established shortly after Lefkofsky’s wife was diagnosed with breast cancer, to use technology and data to improve patient outcomes. The company employs about 2,300 people as of 2024 and has its headquarters at 600 West Chicago Avenue.
 

Tempus builds and operates a large analytical platform that combines clinical and molecular data to support real-time, data-driven medical decisions. Initially focused on oncology, its services now extend to cardiology, radiology, infectious disease, and neuro-psychiatry, as well as pharmacogenomic testing for patients with depression. The company provides tools for physicians to order tests, track results, and match patients to personalised treatment plans, using guidance such as MSK OncoKB and NCCN Guidelines®.
 

Tempus partners with healthcare providers, academic and research centres, and life-science organisations to assist with research, clinical development, and commercialisation of therapies. Its technology products include Hub, One, Now, Lens, Pixel, Next, Link, Assays, and Algos, all designed to connect clinical care with research and create a continuous cycle of data collection and insight.
 

The company has attracted major investors including SoftBank Group, Baillie Gifford, Google, New Enterprise Associates, Novo Holdings, T. Rowe Price, Revolution LLC, and Franklin Templeton. In June 2024, Tempus formed SB Tempus, a joint venture with SoftBank in Japan to develop AI-driven personalised treatments. In November 2024 it agreed to acquire Ambry Genetics for $600 million in cash and stock, expanding its genetic testing capabilities.
 

Tempus’s advisory board features recognised leaders such as Nobel laureate Jennifer Doudna and former FDA Commissioner Scott Gottlieb. Guided by the mission that every patient should benefit from the experience of those who came before, Tempus continues to develop technology that helps doctors deliver the right treatment at the right time, aiming to improve outcomes across a growing range of diseases worldwide.

Tempus AI, Inc. was founded in August 2015 by Eric Lefkofsky, following his wife's breast cancer diagnosis. Frustrated by the lack of data-driven insights in her treatment, Lefkofsky aimed to create a platform that could harness technology and artificial intelligence to improve cancer care. He recruited Ryan Fukushima as the company's first employee, and together they began developing a system to integrate real-time healthcare data for personalised diagnostics.
 

Initially focused on oncology, Tempus expanded its services to include cardiology, radiology, neuropsychiatry, and pharmacogenomic testing for depression. The company developed a platform that combines clinical and molecular data to assist physicians in making informed treatment decisions. By 2024, Tempus had become a leader in precision medicine, serving approximately 50% of oncologists in the United States.
 

In June 2024, Tempus went public on the Nasdaq under the ticker symbol "TEM," aiming to raise $410.7 million. The company was valued at up to $6.1 billion at the time of its initial public offering.
 

Later that year, in November 2024, Tempus acquired Ambry Genetics, a leader in genetic testing, for $600 million. The acquisition, comprising $375 million in cash and $225 million in stock, was financed in part through a $300 million increase in debt provided by Ares Management Credit funds.
 

In June 2024, Tempus partnered with SoftBank Group to establish a joint venture named SB Tempus in Japan. Each company invested ¥15 billion (approximately $93 million) to develop AI-powered precision medicine services in the Japanese market.
 

As of 2025, Tempus continues to lead in the application of artificial intelligence in healthcare, expanding its global presence and enhancing its platform to provide personalised treatment options across various medical disciplines.

Tempus AI’s mission is to revolutionise healthcare by applying artificial intelligence to precision medicine. The company aims to empower healthcare providers with real-time, data-driven insights that enable personalised treatments for patients. By integrating clinical and molecular data, Tempus seeks to improve decision-making in oncology, cardiology, radiology, and other medical fields, ensuring patients receive the most appropriate care. Through ongoing research and technological advancements, Tempus strives to make sure each patient benefits from the experience of those who came before, enhancing health outcomes worldwide.

Tempus AI envisions a future where every patient’s treatment is personalised and optimised using the power of data and artificial intelligence. The company aims to become a global leader in precision medicine, helping healthcare professionals make better decisions based on vast amounts of clinical and molecular data. Tempus seeks to foster a world where AI plays a pivotal role in reducing treatment errors, improving recovery rates, and ultimately saving lives. The goal is to continuously advance healthcare through data-driven insights, making personalised treatments accessible to all patients, no matter their background or location.

In 2017, Tempus AI was honoured with the Most Disruptive Startup award at the Moxie Awards, which recognised innovation within Chicago's tech community. The following year, Tempus was named an Industry Disruptor at the CityLIGHTS Awards, acknowledging its significant impact on the healthcare industry. In 2024, the Centres for Medicare & Medicaid Services (CMS) granted Tempus' xT CDx test Advanced Diagnostic Laboratory Test (ADLT) status, further validating its novel approach to genomic profiling. Additionally, Tempus was nominated for the Medical Research award at the 2025 World AI Awards, underscoring its continued advancements in AI-driven healthcare solutions. These accolades reflect Tempus' dedication to improving patient outcomes through innovative technologies and its increasing influence in the medical technology sector.

Tempus AI offers a comprehensive range of products and services that combine cutting-edge artificial intelligence with clinical data to advance personalised healthcare. Their main focus is to improve patient outcomes by providing healthcare providers with real-time, data-driven insights. Below is a detailed look at the products and services that Tempus provides.
 

Tempus' flagship product is its clinical data platform, which is designed to integrate vast amounts of clinical and molecular data to assist healthcare professionals in making informed treatment decisions. The platform collects data from various sources, including patient records, genomic sequencing, and clinical trials, and uses advanced AI algorithms to process and analyse the information. 

This allows doctors to receive personalised treatment recommendations for their patients, based on a more precise understanding of their genetic makeup and clinical history. The platform has been particularly successful in oncology, where personalised cancer treatments are critical to improving survival rates.
 

In addition to the clinical platform, Tempus offers a suite of genomic testing services. One of the key products in this category is the xT CDx test, which is designed to provide comprehensive genomic profiling for cancer patients. This test identifies genetic mutations that could help doctors select the most effective treatment options. The test is part of Tempus' broader focus on precision oncology, where treatments are tailored to individual patients based on their genetic data. By providing accurate genomic insights, Tempus helps doctors pinpoint targeted therapies that may offer better results than standard treatments.
 

Tempus also provides pharmacogenomic testing for depression. This service helps doctors understand how a patient's genetic makeup affects their response to antidepressant medications. The goal is to find the most suitable medication for each patient, reducing trial-and-error prescribing and improving treatment outcomes. The pharmacogenomic testing is a key part of Tempus' effort to extend the benefits of precision medicine to mental health care.
 

In cardiology, Tempus offers a range of tools to help healthcare providers make more accurate diagnoses and treatment decisions. The platform provides insights into cardiac health by analysing clinical data and genomic information, enabling doctors to assess the risk of cardiovascular diseases and tailor treatments accordingly. This service is particularly valuable in the management of chronic heart conditions, where personalised care can significantly improve patient outcomes.
 

For radiology, Tempus uses AI to assist doctors in interpreting medical imaging more accurately. The company’s AI algorithms can analyse radiological images, such as X-rays and MRIs, to detect abnormalities that might not be visible to the human eye. This is particularly beneficial in early diagnosis, where catching a disease or condition in its initial stages can lead to more successful treatment.
 

Tempus also provides an array of AI-powered solutions for research and clinical development. These tools are designed to help pharmaceutical companies and academic institutions advance the development of new treatments. Tempus’ AI technology can analyse clinical trial data, identify potential drug candidates, and optimise clinical development processes. This accelerates the discovery of new therapies and brings them to market faster.
 

Another important product from Tempus is Hub, a comprehensive platform for healthcare providers that enables them to order tests, manage patient results, and track treatments. This service is designed to streamline the clinical workflow and ensure that no critical tests or steps are missed during the treatment process.